ERICH5

Across TCGA pan-cancer cohorts, ERICH5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ERICH5 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ERICH5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ERICH5 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where ERICH5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.922	0.764	.011	11	view →
CCRCC	OS	Quartile	III,IV	0.877	0.506	.025	7	view →
LUAD	OS	Tertile	All	0.899	0.611	.039	3	view →
UCEC	OS	Quartile	All	0.797	0.961	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ERICH5–PDAC (OS)

Open the PDAC breakdown →